Home > Protocol Summaries: Compounds > GSK2231392A Protocol Summaries: GSK2231392A GSKStudy ID Phase Title Status 112115 phase 2 Comparison of the immunogenicity and safety of various investigational and licensed formulations of Hepatitis B surface antigen (HBsAg) vaccines. Completed 113737 phase 4 A study in healthy adults having received a single vaccine administration to support the development of immunological assays Completed 115315 phase 4 A study in adult subjects with allergy to support the development of immunological assays Completed 116640 phase 2 Development of read-outs to detect and characterise the early and adaptive immune responses in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals’ Adjuvant System Recruiting
